EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Current and Emerging Inhaled Antibiotics for Chronic Pulmonary Pseudomonas aeruginosa and Staphylococcus aureus Infections in Cystic Fibrosis

Danni Li, Elena K Schneider-Futschik iD

Antibiotics · 28.02.2023 · 12 (3) · 484

DOI: 10.3390/antibiotics12030484 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Antibiotics, online erschienen am 28.02.2023. Verfasst von Danni Li und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry & Pharmacology, School of Biomedical Sciences, Faculty of Medicine, Dentistry and Health Sciences, The University of Melbo…. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 119 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHMRC, Cystic Fibrosis Australia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Characterized by impaired mucus transport and subsequent enhanced colonization of bacteria, pulmonary infection causes major morbidity and mortality in patients with cystic fibrosis (CF). Pseudomonas aeruginosa (P. aeruginosa) and Staphylococcus aureus (S. aureus) are the two most common types of bacteria detected in CF lungs, which undergo multiple adaptational mechanisms such as biofilm formation resulting in chronic pulmonary infections. With the advantages of greater airway concentration and minimized systemic toxicity, inhaled antibiotics are introduced to treat chronic pulmonary infection in CF. Inhaled tobramycin, aztreonam, levofloxacin, and colistin are the four most common discussed inhaled antibiotics targeting P. aeruginosa. Additionally, inhaled liposomal amikacin and murepavadin are also in development. This review will discuss the virulence factors and adaptational mechanisms of P. aeruginosa and S. aureus in CF. The mechanism of action, efficacy and safety, current status, and indications of corresponding inhaled antibiotics will be summarized. Combination therapy and the strategies to select an optimal inhaled antibiotic protocol will also be discussed.

Schlagwörter

Stichwörter der Autor:innen

P. aeruginosaS. aureuschronic pulmonary infectionscystic fibrosisinhaled antibiotics

Autor:innen und Institutionen

  • Department of Biochemistry & Pharmacology, School of Biomedical Sciences, Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Parkville, VIC 3010, Australia.

ORCID-Profile: Elena K Schneider-Futschik

Förderung

  • NHMRC
  • Cystic Fibrosis Australia

Zitieren

APA

Li, D., & Schneider-Futschik, E. K. (2023). Current and Emerging Inhaled Antibiotics for Chronic Pulmonary Pseudomonas aeruginosa and Staphylococcus aureus Infections in Cystic Fibrosis. Antibiotics, 12(3), 484. https://doi.org/10.3390/antibiotics12030484

Vancouver

Li D, Schneider-Futschik EK. Current and Emerging Inhaled Antibiotics for Chronic Pulmonary Pseudomonas aeruginosa and Staphylococcus aureus Infections in Cystic Fibrosis. Antibiotics. 2023;12(3):484. doi:10.3390/antibiotics12030484

BibTeX
@article{Li2023,
  author = {Li, Danni and Schneider-Futschik, Elena K},
  title = {Current and Emerging Inhaled Antibiotics for Chronic Pulmonary Pseudomonas aeruginosa and Staphylococcus aureus Infections in Cystic Fibrosis},
  journal = {Antibiotics},
  year = {2023},
  volume = {12},
  number = {3},
  pages = {484},
  doi = {10.3390/antibiotics12030484}
}
Kostenlos starten →